Introduction
The prevalence of heart failure (HF) is increasing worldwide, with rising costs to society. In an effort to prevent symptomatic HF (stages C and D), guidelines suggest to identify subjects with risk factors for HF or characterized by structural/functional myocardial abnormalities without signs or symptoms of HF (HF stages A and B).
1 In these groups of subjects, preventive strategies are endorsed to reduce the burden of HF. However, the implementation of these strategies is still suboptimal due to barriers at the patient, health care provider, and health system level, which do not allow the implementation of optimal primary and secondary prevention. 2, 3 These data emphasize the need to refine HF risk stratification to better identify higher and lower risk individuals. Among structural/functional myocardial abnormalities, mild systolic dysfunction (both asymptomatic and symptomatic) is gaining the most attention, because it affects a sizable proportion (10-20%) of the HF population. 4 -15 Importantly, mild asymptomatic left ventricular systolic dysfunction (ALVSD) predicts HF and death, and risk factor control is recommended by guidelines.
1,4 -6,16 Yet, further refining incident HF risk might improve resource allocation and allow the implementation of tailored preventive strategies in mild ALVSD, in particular to identify subjects at highest risk, who may derive the greatest benefit.
Left ventricular (LV) diastolic dysfunction (DD) has also been described as a condition that puts patients at risk for incident HF and mortality in community studies.
17 -22 However, its value in the risk stratification of patients with mild ALVSD is unknown. Of note, previous data have shown pharmacological improvement of LV diastolic function in hypertensive heart disease. 23 Furthermore, left atrial volume decrease at follow-up was associated with a lower risk of the subsequent occurrence of cardiovascular events in patients with HF. 24 Thus, the detection and counteraction of asymptomatic DD may be important for reducing the burden of clinical HF, especially considering the lack of effective treatment for patients with symptomatic HF and LV ejection fraction (LVEF) ≥ 40%. 1, 16 In this context, we assessed risk prediction for HF/death according to mild ALVSD and presence or absence of DD in this post-hoc analysis of the DAVID-Berg (Detection of Asymptomatic VentrIcular Dysfunction in Bergamo) study, comprising a population at high risk for HF (stages A and B).
Methods

Study population
The DAVID-Berg study 25 -27 was a prospective cohort study carried out at three primary care group practices in northern Italy, comprising 10 general practitioners. In 2008, each primary care physician reviewed the clinical records of all subjects aged 55 to 80 years (n = 4047). Within this age stratum, 113 subjects (2.8%) had known or suspected HF, as defined by the European Society of Cardiology guidelines 16 (i.e. symptoms and signs of HF associated with objective evidence of structural or functional abnormalities of the heart at rest). Patients without known or suspected HF, without congenital heart disease (n = 3), or moderate-to-severe valvular heart disease (n = 11) were included. From Finally, the DAVID-Berg study population comprised 623 subjects who underwent a protocol consisting of history and physical examination (including height, weight, and blood pressure measurement), electrocardiogram, lipid profile, fasting blood glucose, glycosylated haemoglobin, creatinine, N-terminal pro B-type natriuretic peptide (NT-proBNP), and comprehensive echocardiographic evaluation ( Figure 1) . Renal function was assessed by estimating glomerular filtration rate (eGFR) with the simplified Modification of Diet in Renal Disease equation. Renal dysfunction was defined as an eGFR <60 mL/min/1.73 m 2 .
All patients provided written informed consent to participate in the study, which was approved by the ethics committee of the Local Health Authority.
Natriuretic peptide analysis
NT-proBNP was measured with competitive enzyme immunoassay (Cobas h232, Roche Diagnostics). As both sex and age significantly impact NT-proBNP plasma values, we used cut-points corresponding to age-and sex-adjusted 80th percentile values for NT-proBNP, and NT-proBNP was considered abnormal when greater than age-/sex-specific 80th percentiles. 28 
Echocardiographic study
The echocardiograms were obtained using a Vivid I GE medical ultrasound machine with a 2.5 MHz transducer (GE Medical System, Horten, Norway). All examinations were performed by cardiologists expert in echocardiography. For quality assurance, randomly (n = 50) chosen echo examinations were reviewed by the echo core lab at Papa Giovanni XXIII Hospital, Bergamo, Italy, with an intra-class correlation of 0.93 for LVEF and 0.91 for septal mitral annulus E'. All measurements were made in triplicate in patients in sinus rhythm, while in those with atrial fibrillation measurements were averaged over 10 R-R cycles, in accordance with the recommendations of the American Society of Echocardiography and the European Association of Cardiovascular Imaging. 29 LV volumes and LVEF were derived according to the modified biplane Simpson's method in the apical four-chamber and two-chamber views. LV mass (LVM) was calculated from LV linear dimensions and indexed to height 2.7 . LV hypertrophy was defined as LVM indexed to height 2.7 > 44 g/m 2.7 in women and > 48 g/m 2.7 in men.
Left ventricular ejection fraction and DD data were analysable in 614 patients. LVEF was classified as normal (≥53%), mildly reduced (40-52%), or reduced (<40%), in accordance with recently updated echocardiography guidelines. 29 We defined DD based on widely accepted diastolic function parameters with validated cut-offs and prognostic relevance, such as left atrial volume index (LAVi, abnormal >34 mL/m 2 ), septal E' (abnormal <0.07 m/s), and septal E/E' (abnormal >15). 20, 30, 31 To improve diagnostic accuracy, we classified DD presence in the case of two abnormal diastolic parameters out of three. Based on LVEF and DD at baseline evaluation, participants were divided into three categories as follows: control group (LVEF ≥53%, n = 459, 76%), mild ALVSD (LVEF ≥40%/<53%) without DD (n = 89, 15%), and mild ALVSD with DD (n = 54, 9%). Subjects with LVEF <40% were excluded from the analysis (n = 12).
Clinical follow-up
Between September 2008 and June 2014, data on HF and all-cause death events were collected prospectively. The outcome of interest was a composite of HF events and all-cause death, whichever occurred first. Incident HF was defined as hospital admission for HF (identified by inpatient ICD-9 code 428.xx with HF as primary diagnosis), or as a clinical outpatient event in the case of appearance of HF signs and symptoms associated with changes in diuretic therapy (introduction of loop diuretics or increase in dose of other classes of diuretics). 21, 32, 33 Inpatient and outpatient events were recorded by adequately trained general practitioners during the study time frame and adjudicated by two independent cardiologists in June 2014. If the two cardiologists disagreed, a third cardiologist adjudicated the event.
. 
Statistical analyses
Log transformation was applied to skewed variables (NT-proBNP). Continuous variables were expressed as mean ±standard deviation, or median (25th-75th percentile) if non-parametric, while categorical variables were presented as percentages of observations. Clinical characteristics and cardiovascular structure and function were compared, according to LVEF groups and to mild ALVSD with or without DD, with the Chi-square test, Fisher exact test, rank-sum test, or t-test, as determined by variable type and distribution.
Predictors of the composite outcome were assessed via univariate and multivariate Cox regression analyses. Adjusted models were developed with consideration for age, sex, and relevant variables having P < 0.1 by univariate analyses (heart rate, smoking status, presence of CVD, total cholesterol, diabetes mellitus, atrial fibrillation, abnormal NT-proBNP, DD, and LVEF). To assess the prognostic importance of mild ALVSD with or without DD, the risk of the composite outcome was assessed according to the three LVEF/DD groups. Predictors of the primary composite outcome and of its individual components were also analysed using Cox stepwise multivariate analysis.
Given that evaluation of diastolic function in patients with atrial fibrillation during the echocardiographic examination may be cumbersome, we performed a sensitivity analysis, excluding subjects with atrial fibrillation (n = 21). Additionally, we assessed whether there was a higher rate of clinical events in patients with normal LVEF and DD (compared to those without DD in the normal LVEF group) through another sensitivity analysis. We also formally tested if there was interaction between the LVEF and DD groups. The assumption of proportional hazards was tested using Schoenfeld residuals and was met for all analyses reported.
Kaplan-Meier survival curves of the three LVEF/DD groups were plotted, and differences were tested for significance using the log-rank test. A two-sided P-value of <0.05 was considered statistically significant. All statistical analyses were performed using Stata version 13.0 (Stata Corp., College Station, TX, USA).
Results
Overall, the mean age of the study population was 69 years, 56% were men, mostly hypertensive (88%), one-third had diabetes mellitus, half had a history of CVD, and one-fourth had renal dysfunction (eGFR <60 mL/min/1.73 m 2 ) ( Table 1 ). The majority of the population was treated with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) (70%). The median NT-proBNP was 177 pg/mL, mean septal E/E' was 10.7, and mean LAVi was 30 mL/m 2 . Approximately one-third of the population had DD (34%), two-thirds had LV hypertrophy, while mean LVEF was 61% ( Table 1) .
According to LVEF categories, one-fourth of the study population had mild ALVSD. Compared to the control group (i.e. normal LVEF), subjects with mild ALVSD were more frequently males, had . a higher prevalence of a known history of CVD (including myocardial infarction), were more often treated with statins, and had a higher prevalence of atrial fibrillation. Additionally, they had a higher LVM index. According to diastolic function parameters, subjects with mild ALVSD had a higher LAVi and E/A ratio, with higher NT-proBNP ( Table 1 ).
In comparison with ALVSD without DD, patients with DD were less likely to be smokers, had lower body mass index, more atrial fibrillation, and a greater prevalence of beta-blocker therapy. These differences were associated with higher NT-proBNP, E/A, E/E', and LAVi in the group with DD compared to that without it ( Table 2) . the control group and 4.5 per 100 person-years with mild ALVSD (P = 0.001). Based on the three LVEF/DD groups (Figure 2) , the event rate ranged from 2.1 per 100 person-years (control group) to 3.1 per 100 person-years (mild ALVSD without DD) and 6.9 per 100 person-years (mild ALVSD with DD) (P < 0.001). Univariate predictors of the composite outcome were age, heart rate, smoking status, total cholesterol, diabetes mellitus, atrial fibrillation, abnormal NT-proBNP, presence of DD, and mild ALVSD. At multivariate analysis, independent predictors of the composite outcome were age, smoking status, diabetes mellitus, known CVD, . . In a sensitivity analysis excluding subjects with atrial fibrillation, we obtained similar results (ALVSD with DD vs. control group: HR 3.70, 95% CI 1.88-7.28, P < 0.001; ALVSD without DD vs. control group: HR 1.51, 95% CI 0.82-2.79, P = 0.18). Another sensitivity analysis comparing subjects with normal LVEF and diastolic function (n = 307) to subjects with normal LVEF but with DD (n = 152) showed that the presence of DD, even in subjects with normal LVEF, was associated with a worse prognosis (HR 1.94, 95% CI 1.08-3.51, P = 0.028). Concordantly, there was no interaction between LVEF groups (normal vs. mild ALVSD) and DD groups (DD present vs. absent), since DD had prognostic importance across the entire spectrum of LVEF.
Discussion
In this community general medical practice cohort of individuals aged 55 to 80, mild ALVSD was common (24%) and one-third of the population had DD. Compared to subjects with normal systolic function, those with mild ALVSD had a higher risk of HF and death over a median follow-up of 5.7 years. However, this greater risk was present mainly in subjects with combined DD, as opposed to those with normal diastolic function. Our data suggest that one way to help distinguish high-from low-risk subjects with mild ALVSD is to risk stratify according to DD.
High-risk populations gain the most from preventive strategies and the implementation of exams, such as natriuretic peptide, high-sensitivity troponin testing, and echocardiography.
17,34 -38 Specifically, echocardiography allows the early detection of asymptomatic systolic and diastolic dysfunction, which may be precursors of symptomatic HF. 21 In this setting, the DAVID-Berg data show that mild ALVSD and DD are associated with incident HF/death in HF stages A and B, possibly making them ideal candidates for early behavioural-therapeutic interventions. Preventive strategies, such as adequate risk factor control, frequent clinical follow-up, exercise training, and an aggressive pharmacological intervention might decrease or limit incident HF, especially in this higher risk subgroup, which was characterized by higher natriuretic peptide values as compared to both the group with normal systolic function and the one with mild ALVSD associated with normal diastolic function. 39 Of note, an echocardiographic examination is normally performed in at-risk subjects, such as those evaluated in the DAVID-Berg study. Thus, our suggestion is that an echocardiographic exam, providing information not only on systolic function but also on simple and commonly acquired diastolic parameters, might be used to select patients with mild ALVSD who would be more suitable for the aforementioned targeted interventions.
Although risk factor control is endorsed by current guidelines in subjects with mild ALVSD, 1,16 suboptimal implementation of preventive strategies has been shown in community settings comprising stages A and B of HF. 2, 3 Indeed, the suboptimal blood pressure control in the DAVID-Berg cohort, despite the frequent treatment with ACEi and ARBs, and the significant association between smoking habits and adverse outcomes further strengthen the importance of adequate counselling and intervention in at-risk populations. 40 Moreover, prevention is mandatory, considering that nowadays symptomatic (stages C and D) HF with preserved LVEF does not have a recognized effective therapy, despite its growing burden and prevalence. has already been acknowledged that ALVSD with reduced LVEF (<40%) represents a subgroup of patients that deserves cardiologist counselling and with demonstrated benefit from therapies such as ACEi. 43 According to DAVID-Berg data, the prevalence of subjects with combined mild ALVSD and DD was definitely higher than that of subjects with reduced LVEF (9% vs. 2%), thus its identification could potentially have a greater impact on clinical HF.
Despite the lack of effective treatments for HF with preserved LVEF, data from the CHARM-Preserved trial seem to suggest improved outcome with the ARB candesartan in patients with mid-range LVEF. 7 Furthermore, a recent post-hoc analysis of the TOPCAT trial showed that the potential efficacy of spironolactone was greatest at the lower end of the LVEF spectrum (between 45% and 50%), 8 with HRs for the primary outcome of cardiovascular death and HF hospitalization similar to those observed in mineralocorticoid receptor antagonists (MRAs) trials in patients with reduced LVEF. 8 These data indicate that therapies validated in HF with reduced LVEF, such as MRAs, ACEi, or ARBs, may be effective in HF with mild systolic dysfunction, ideally and especially in its asymptomatic phases (stages A and B), when structural and functional abnormalities are more likely to be less advanced and may consequently be treatable and reversible.
In previous community-based studies of ALVSD, participants with a mild reduction in LVEF were found to have a poorer prognosis compared to those with normal LVEF. 4 -6 However, data on both systolic and diastolic dysfunction were not reported. Our study, considering the cumulative incidence of HF and all-cause death, showed that, taking into account DD presence, mild ALVSD remained associated with adverse prognosis in case of combined systolic/diastolic dysfunction, while the mere presence of isolated ALVSD did not confer a worse outcome compared to the control group. Due to the relatively high frequency of ALVSD and DD encountered (approximately 10%), DAVID-Berg data suggest looking for this combination. Of note, it could be argued that in a larger population mild ALVSD might be associated with impaired prognosis even in subjects without DD. However, in an era of spending reviews and characterized by an increasing burden of HF, we have to properly allocate resources, concentrating our efforts and preventive strategies on higher risk subjects, such as those with ALVSD and DD, who suffer from the well-known negative effects of both systolic and diastolic dysfunction.
Study limitations
The limitations of this analysis should be noted. First, despite the multivariate analyses, residual confounding cannot be excluded. these results in larger populations and different study settings is essential. Second, the inclusion and exclusion criteria of the DAVID-Berg study limit the generalizability of our results to other community settings. In particular, the DAVID-Berg study included only Caucasian participants. Nonetheless, DAVID-Berg baseline characteristics are similar to those described in other communities, such as in Olmsted County, Minnesota. 20 Third, LVEF was determined only at baseline and it is conceivable that LVEF measurements are not static over time in a single patient, possibly leading to some misclassification. Additionally, it could be argued that the LVEF cut-offs defined for this study were arbitrary. However, taking into consideration the LVEF thresholds used in studies reporting the characteristics of the mid-range subgroup, 7, 44 and in particular the European and American echocardiographic guidelines which define a LVEF ≥53% as normal, 29 we applied the cut-off that distinguishes normal from abnormal systolic function by echocardiography. Of note, results did not change whether considering the LVEF cut-off of 55% (data not shown), or a cut-off of 50% (ALVSD with DD vs. control group: HR 3.67, 95% CI 1.55-8.66, P = 0.003; ALVSD without DD vs. control group: HR 1.51, 95% CI 0.60-3.80, P = 0.38).
Conclusion
Our study suggests that, in populations at risk for HF, mild ALVSD and DD represent a quite common and ominous combination. These data may spur further research to ascertain whether the implementation of preventive strategies might avoid the transition from mild ALVSD with DD to the symptomatic phase.
